We are live on ! Find out more
KITE

Kite Pharma
KITE

Delisted

KITE was delisted on the 2nd of October, 2017.

116 hedge funds and large institutions have $1.21B invested in Kite Pharma in 2014 Q4 according to their latest regulatory filings, with 56 funds opening new positions, 40 increasing their positions, 8 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

700% more first-time investments, than exits

New positions opened: 56 | Existing positions closed: 7

579% more capital inflows, than outflows

Capital inflows: $415M | Capital outflows: $61.1M

400% more funds holding in top 10

Funds holding in top 10: 1 → 5 (+4)

400% more repeat investments, than reductions

Existing positions increased: 40 | Existing positions reduced: 8

87% more funds holding

Funds holding: 62 → 116 (+54)

25.2% less ownership

Funds ownership: 25.2% → 0% (-25%)

57% less call options, than puts

Call options by funds: $3.76M | Put options by funds: $8.64M

Holders
116
Holders Change
+54
Holders Change %
+87.1%
% of All Funds
3.08%
Holding in Top 10
5
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+400%
% of All Funds
0.13%
New
56
Increased
40
Reduced
8
Closed
7
Calls
$3.76​M
Puts
$8.64​M
Net Calls
-⁠$4.89​M
Net Calls Change
-⁠$4.89​M

KITE Hedge Fund Activity: Q4 2014 in Review

116 of the 3,765 institutional investors tracked by Wall St. Rank reported a position in Kite Pharma (KITE) for Q4 2014, worth a combined $1.21B — up 342% from $273M a quarter earlier.

Buyers outnumbered sellers: 56 funds opened new KITE positions and 7 closed out — a net gain of 49 holders — while 40 added to existing stakes and 8 trimmed.

The largest buyer was Capital Research Global Investors, adding an estimated $61.8M. The largest seller was Deerfield Management, cutting an estimated $36M.

  • 116 institutional investors held Kite Pharma (KITE) as of Q4 2014, up from 62 in Q3 2014.
  • Funds reported $1.21B of Kite Pharma stock for Q4 2014, up 342% quarter-over-quarter.
  • 56 funds opened new Kite Pharma positions in Q4 2014 and 7 closed out, a net change of +49 holders.
  • The largest Kite Pharma buyer in Q4 2014 was Capital Research Global Investors, an estimated $61.8M added.
  • The largest Kite Pharma seller in Q4 2014 was Deerfield Management, an estimated $36M sold.

Based on aggregated 13F filings for Q4 2014.